|
David Allan, MD FRCP(C)
daallan@ohri.ca
Telephone: 613-737-8899 ext. 71284
Fax: 613-737-8861
 General Campus
(see Contact page for maps)
|
Associate Scientist, Regenerative Medicine, Ottawa Hospital Research Institute
Assistant Professor, Division of Hematology, Department of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa
Adjunct Scientist, Canadian Blood Services
Biographical Sketch
Dr. Allan graduated from the MD program at Queen's University in 1997 and completed residency in Internal Medicine and Hematology and the University of Toronto and University of Western Ontario, respectively. As a post-MD research fellow at Robarts Reseach Institute, he studied the plasticity and regenerative function of hematopoietic stem cells. Prior to joining the Division of Hematology and Blood & Marrow Transplant Program at The Ottawa Hospital in 2005, Dr. Allan completed a clinical fellowship in blood and marrow transplantation at the Maisonneuve-Rosemont Hospital in Montreal.
Research Interests
Ongoing research addresses the cellular and molecular determinants of regenerative function in blood-derived vascular progenitor cells. Vascular repair is crucial for tissue regeneration in several models of ischemic tissue injury, including the repair of transplant-related toxicity following bone marrow transplantation (BMT). Additional studies focus on the role of mesenchymal stromal cells in immune modulation and tissue repair. Translational research projects and clinical trials involving blood-derived stem cells also comprise an important aspect of Dr. Allan's research program. Research in Dr. Allan's laboratory is funded by CIHR, NSERC, Canadian Blood Services, The Ottawa Hospital Foundation and the Department of Medicine.
Selected Honours and Awards
2009 - CIHR New Investigator Award
2004 - Fujisawa, Canada Inc. Bone Marrow Transplant Fellowship Award
2002 - Leukemia Research Fund of Canada Postdoctoral Fellowship Award
2002 - National Cancer Institute of Canada Terry Fox Post-MD Research Award (declined)
1999 - Canadian Hematology Society Resident Research Award
Selected Publications (past 5 years)
Takach S, Yang L, Ho J, Sabri E, Martin L, Halpenny M, Atkins H, Sabloff M, McDiarmid SA, Huebsch LB, Bence-Bruckler I, Giulivi A, Allan DS. Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation. Bone Marrow Transplant, 2009 (in press).
Allan DS, Takach S, Smith S, Goldman M. Impact of declining fertility rates on donor options in blood and marrow transplantation. Biol Blood Marrow Transplant, 2009 (in press).
Hamadah A, McDiarmid SA, Huebsch LB, Patel R, Allan DS. Management of patients transferred to ICU during the conditioning phase of allogeneic hematopoietic stem cell transplantation. Intensive Care Med, 2009 (in press)
Allan DS, Morgan SC, Birch PE, Yang L, Halpenny M, Eapen L. Circulating vascular progenitors are mobilized in cancer patients receiving external beam radiation in response to tissue injury. Int J Rad Onc Biol Phys, 2009; (in press).
Labonté L, Li C-Y, Yang L, Gillingham A, Halpenny M, Giulivi A, Sills T, Evans K, Zanke B, Allan DS. Increased plasma EPO and MIP-1 are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts. Exp Hematol, 2009; 37:673-8.
Ho J, Yang L, Banihashemi B, Martin L, Halpenny M, Atkins H, Sabloff M, McDiarmid SA, Huebsch LB, Bence-Bruckler I, Giulivi A, Allan DS. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant, 2009; 43:223-8.
Labonté L, Iqbal T, Zaidi MA, McDiarmid SA, Huebsch LB, Tay J, Atkins H, Allan DS. Utility of co-morbidity assessment in predicting transplant-related toxicity following autologous hematopoietic transplantation for multiple myeloma. Biol Blood Marrow Transplant, 2008; 14:1039-44.
Gonsalves A, Carrier M, Wells PS, McDiarmid S, Huebsch L, Allan DS. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost, 2008; 6:1468-73.
Kasbia G, Al-Gahtani F, Tay J, Labonté L, Tinmouth A, Ramsay T, Gillingham A, Yang L, Halpenny M, Giulivi A, McDiarmid S, Huebsch L & Allan DS. Reduced hemoglobin on day of PBPC collection influences graft content of vascular progenitors and organ toxicity following autologous hematopoietic stem cell transplantation. Transfusion, 2008; 48:2421-28.
Iqbal T, Rajagopal T, Halpenny M, Yang L, Martin L, Giulivi A, McDiarmid S, Huebsch L & Allan DS. Increased graft content of vascular progenitor cells is associated with reduced toxicity following autologous hematopoietic transplantation. Exp Hemat, 2008;36:506-12.
Labonté L, Iqbal T, McDiarmid S, Bence-Bruckler I, Huebsch L & Allan DS. Erythropoietin during PBPC collection: can we reduce toxicity of autologous transplants in multiple myeloma. Biol Blood and Marrow Transplantation, 2008; 14:132-3 [letter]
Allan DS, Dubé P, Roy J, Busque L, Roy DC. Endothelial-like vascular progenitor cells from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors. Biol Blood and Marrow Transplantation, 2007; 13:433-9.
Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid in the prevention of hepatic veno-occlusive disease following hematopoietic transplantation. Biol Blood and Marrow Transplantation, 2007; 13:206-17.
Allan DS, Bélanger R, Busque L, Cohen S, Fish D, Roy DC & Roy J. Maintaining high autopsy rates in a Canadian Blood and Marrow Transplant Program: preserving a diagnostic and research tool. Bone Marrow Transplant, 2005; 35:781-5.
Allan DS, Gallacher L, Keeney M, Bhatia M, Chin-Yee IH, Xenocostas A. Undetectable leukemic blasts and absence of NOD/SCID leukaemia-initiating cells in cord blood from a case of maternal AML. Bone Marrow Transplant, 2005; 36:269-70 [letter].
Allan DS, Jay KE & Bhatia M. Hematopoietic capacity of adult human skeletal muscle is negligible. Bone Marrow Transplant, 2005; 35:663-6.
| |
